

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

SUPPLEMENTAL ANNOUNCEMENT
RESIGNATION OF EXECUTIVE DIRECTOR;
APPOINTMENT OF EXECUTIVE DIRECTORS; AND
CHANGE OF AUTHORIZED REPRESENTATIVE

Reference is made to the announcement of the Company dated 27 August 2026 (the “**Announcement**”) in relation to, among other things, the Resignation of Executive Director; Appointment of Executive Directors; and Change of Authorized Representative with effect from 27 August 2026. Unless otherwise defined, capitalised terms herein shall have the same meanings as defined in the Announcement.

The Company would like to further elaborate that Dr. Yiping Rong resigned as an executive Director in order to better allocate his time and efforts to his other business commitments.

All information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
*Chairman and Executive
Director*

Hong Kong, 2 September 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang, Mr. Youchen Chen and Dr. Ian Yi Liu as executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.